Long-coronavirus disease 2019 (COVID-19) represents a heterogeneous clinical syndrome
characterized by a pathologic continuum of signs, symptoms, and also laboratory/radiologic …

Background Coagulopathy is a common abnormality in patients with COVID‐19. However,
the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to a worldwide
pandemic, and patients with the infection are referred to as having COVID‐19. Although …

It is well established that the risk of venous thromboembolism is high in coronavirus disease
19 (COVID-19). The frequency of arterial thromboembolic events (ATEs) in hospitalized …

May 4, 2020, there are> 1.2 million confirmed cases in the United States and> 66 000
deaths. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and …

Background Although thrombosis events have been reported in COVID-19 patients, the
association between thrombosis and COVID-19-related critical status or risk of mortality in …

While acute respiratory infections are known to increase thrombosis risk [1], the incidence of
venous thromboembolic events (VTE) in patients with coronavirus disease 2019 (COVID-19) …

Dear Editor, We read with interest the study published by Tang et al1 in a recent issue of the
Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the …

COVID-19 is associated with a variety of clinical complications including coagulopathy,
which frequently results in venous thromboembolism (VTE). Retrospective analyses …